1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40

1. A compound of formula (I)

wherein:

A is —X 1 — or —X 1 —OC(R 9 )(R 10 )—, wherein

X 1 is an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and

R 9 and R 10 , which are identical or different each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH

R 1 and R 2 , which are identical or different each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

R 3 , R 4 and R 8 , which are identical or different each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, —OH, —N(R′)(R″), —N(R′)COR″, —CN, —CONR′R″, —SO 2 NR′R″, —SO 2 R′, or nitro and trifluoromethyl, wherein R′ and R″ are identical or different each other, and are represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R 5 is hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, —OH, —N(R′)(R″), —N(R′)COR″, or nitro and trifluoromethyl, or R 5 together with one of R 6 and R 7 forms a ring having 5 or 6 carbon atoms, wherein R′ and R″ are identical or different each other, and are represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R 6 and R 7 , which are identical or different each other, are hydrogen, or an alkyl group having from 1 to 5 carbon atoms, or R 6 and R 7 together form a group C═O, or one of R 6 and R 7 , together with R 5 , forms a ring having 5 or 6 carbon atoms,

wherein when A is an unsubstituted methylene group or a methylene group substituted with one or more alkyl groups having 1 to 5 carbon atoms, at least one of R 3 to R 8 is not a hydrogen,

or a pharmaceutically acceptable salt thereof, an ester thereof or a prodrug thereof.

2. The compound according to claim 1 , wherein X 1 is an alkyl group having from 1 to 3 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 3 carbon atoms or one or more alkoxy groups having 1 or 2 carbon atoms,

or a pharmaceutically acceptable salt thereof, an ester thereof or a prodrug thereof.

3. The compound according to claim 1 , wherein X 1 is selected from the group consisting of a group CH 2 , a group CH 2 CH 2 , and a group C(CH 3 ) 2 , and R 9 and R 10 , which are identical or different each other, are hydrogen or a CH 3 group,

or a pharmaceutically acceptable salt thereof, an ester thereof or a prodrug thereof.

4. The compound according to claim 1 , wherein residue A is selected from the group consisting of a group CH 2 , a group CH 2 CH 2 , a group C(CH 3 ) 2 , a group CH 2 CH 2 OCH 2 , a group CH 2 CH 2 OC(CH 3 ) 2 and a group CH 2 CH 2 CH 2 OC(CH 3 ) 2 ,

or a pharmaceutically acceptable salt thereof, an ester thereof or a prodrug thereof.

5. The compound according to claim 1 , wherein R 3 , R 4 and R 8 , which are identical or different each other, are selected from the group consisting of a hydrogen atom, an alkyl group having from 1 to 3 carbon atoms, an alkoxy group having 1 or 2 carbon atoms, a Br, Cl or F atom, an OH group, a nitro group, a trifluoromethyl group, a group N(R′)(R″), —N(R′)COR″, —CN, —CONR′R″, —SO 2 NR′R″, and —SO 2 R′, wherein R′ and R″ are identical or different each other, and are represented by a hydrogen atom and an alkyl group having from 1 to 3 carbon atoms,

or a pharmaceutically acceptable salt thereof, an ester thereof or a prodrug thereof.

6. The compound according to claim 1 , wherein R 5 is selected from the group consisting of a hydrogen atom, an alkyl group having from 1 to 3 carbon atoms, an alkoxy group having 1 or 2 carbon atoms, a halogen atom, and an OH group, or R 5 , together with one of R 6 and R 7 , forms a ring having 5 or 6 carbon atoms,

or a pharmaceutically acceptable salt thereof, an ester thereof or a prodrug thereof.

7. The compound according to claim 1 , wherein R 6 and R 7 , which are identical or different each other, are selected from the group consisting of a hydrogen atom, and an alkyl group having from 1 to 3 carbon atoms; or R 6 and R 7 together form a group C═O, or one of R 6 and R 7 , together with R 5 , forms a ring having 5 or 6 carbon atoms,

or a pharmaceutically acceptable salt thereof, an ester thereof or a prodrug thereof.

8. A pharmaceutical composition comprising the compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt, ester or prodrug thereof, and at least one pharmaceutically acceptable vehicle.

9. The pharmaceutical composition according to claim 8 , wherein the pharmaceutically acceptable salt is an additional salt having a physiologically acceptable organic or mineral acid or base.

10. The pharmaceutical composition according to claim 9 , wherein the physiologically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, ascorbic acid, benzoic acid, citric acid, fumaric acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-toluenesulfonic acid, benzenesulfonic acid, succinic acid, tannic acid and tartaric acid.

11. The pharmaceutical composition according to claim 9 , wherein the physiologically acceptable base is selected from the group consisting of ammonium hydroxide, calcium hydroxide, magnesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, arginine, betaine, caffeine, choline, N,N-dibenzylethylene-diamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, N-methylglucamine, glucamine, glucosamine, histidine, N-(2-hydroxyethyl)piperidine, N-(2-hydroxyethyl)pyrrolidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, theobromine, triethylamine, trimethylamine, tripropylamine and tromethamine.

12. The pharmaceutical composition according to claim 8 , wherein the pharmaceutically acceptable ester is formed with a physiologically acceptable organic acid or alcohol.

13. The pharmaceutical composition according to claim 8 , wherein the composition comprises a stereoisomer or an enantiomer of the compound of formula (I), or a pharmaceutically acceptable salt, ester or prodrug thereof, or a mixture thereof.

14. The pharmaceutical composition according to claim 8 , wherein the pharmaceutically acceptable vehicle is selected from the group consisting of a glidant, a binder, a disintegrant, a filler, a diluent, a flavoring, a colorant, a fluidizer, a lubricant, a preserving agent, a humectant, an absorbent, and a sweetener.

15. A method for treating a disease having expression of MCP-1, CX3CR1 and p40, comprising administering an effective amount of a compound of formula (I), a pharmaceutically acceptable salt thereof, an ester thereof or a prodrug thereof to a living being in need thereof

wherein:

A is —X 1 — or —X 1 —OC(R 9 )(R 10 )—, wherein

X 1 is an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and

R 9 and R 10 , which are identical or different each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH,

R 1 and R 2 , which are identical or different each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

R 3 , R 4 and R 8 , which are identical or different each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, —OH, —N(R′)(R″), —N(R′)COR″, —CN, —CONR′R″, —SO 2 NR′R″, —SO 2 R′, or nitro and trifluoromethyl; wherein R′ and R″, are identical or different each other, and are represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R 5 is hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, —OH, —N(R′)(R″), —N(R′)COR″, or nitro and trifluoromethyl, or R 5 together with one of R 6 and R 7 forms a ring having 5 or 6 carbon atoms, wherein R′ and R″ are identical or different each other, and are represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R 6 and R 7 , which are identical or different each other, are hydrogen, or an alkyl group having from 1 to 5 carbon atoms, or R 6 and R 7 together form a group C═O, or one of R 6 and R 7 , together with R 5 , forms a ring having 5 or 6 carbon atoms,

wherein when A is an unsubstituted methylene group or a methylene group substituted with one or more alkyl groups having 1 to 5 carbon atoms, at least one of R 3 to R 8 is not a hydrogen.

16. The method according to claim 15 , wherein the disease having the expression of MCP-1 and CX3CR1 is selected from the group consisting of articular diseases, renal diseases, cardiovascular diseases, metabolic syndrome, obesity, diabetes, insulin resistance and cancer.

17. The method according to claim 15 , wherein the disease comprising the expression of MCP-1 is selected from the group consisting of rheumatoid arthritis, arthritis induced by a viral infection, psoriatic arthritis, arthrosis, lupus nephritis, diabetic nephropathy, glomerulonephritis, polycystic kidney disease, interstitial lung disease, fibrosis, multiple sclerosis, Alzheimer's disease, HIV-associated dementia, atopic dermatitis, psoriasis, vasculitis, restenosis, atherosclerosis, myocardial infarction, angina, acute coronary diseases, adenomas, carcinomas and metastases, metabolic diseases and a complication following a surgical intervention.

18. The method according to claim 15 , wherein the disease comprising the expression of CX3CR1 is selected from the group consisting of rheumatoid arthritis, lupus nephritis, diabetic nephropathy, Crohn's disease, ulcerative colitis, coronary disorders, restenosis, atherosclerosis, myocardial infarction, angina, and a complication following a surgical intervention.

19. The method according to claim 15 , wherein the disease having the expression of p40 is selected from the group consisting of an autoimmune disease, a chronic degenerative inflammatory disease, and cancer.

20. The method according to claim 15 , wherein the disease comprising the expression of p40 is selected from the group consisting of rheumatoid arthritis, psoriasis, glomerulonephritis, diabetes, lupus erythematosus, diabetes, Crohn's disease, and a tumor.

21. A method for treating a disease having expression of CX3CR1 and p40, selected from the group consisting of lupus nephritis, diabetic nephropathy, Crohn's disease, ulcerative colitis, coronary disorders, restenosis, myocardial infarction, angina, a chronic degenerative inflammatory disease, psoriasis, type II diabetes, a tumor, and cancer, comprising administering an effective amount of a compound of formula (I), a pharmaceutically acceptable salt thereof, an ester thereof or a prodrug thereof to a person in need thereof:

wherein:

A is —X 1 — or —X 1 —OC(R 9 )(R 10 )—, wherein

X 1 is an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and

R 9 and R 10 , which are identical or different each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH,

R 1 and R 2 , which are identical or different each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

R 3 , R 4 and R 8 , which are identical or different each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, —OH, —N(R′)(R″), —N(R′)COR″, —CN, —CONR′R″, —SO 2 NR′R″, —SO 2 R′, or nitro and trifluoromethyl, wherein R′ and R″ are identical or different each other, and are represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R 5 is hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, —OH, —N(R′)(R″), —N(R′)COR″, or nitro and trifluoromethyl, or R 5 together with one of R 6 and R 7 forms a ring having 5 or 6 carbon atoms, wherein R′ and R″ are identical or different each other, and are represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms, and

R 6 and R 7 , which are identical or different each other, are hydrogen, or an alkyl group having from 1 to 5 carbon atoms, or R 6 and R 7 together form a group C═O, or one of R 6 and R 7 , together with R 5 , forms a ring having 5 or 6 carbon atoms.

22. A method for treating a disease having expression of MCP-1, CX3CR1 and p40, comprising administering an effective amount of a compound of formula (I), a pharmaceutically acceptable salt thereof, an ester thereof or a prodrug thereof to a person in need thereof:

wherein:

A is —X 1 — or —X 1 —OC(R 9 )(R 10 )—, wherein

X 1 is an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and

R 9 and R 10 , which are identical or different each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH

R 1 and R 2 , which are identical or different each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

R 3 , R 4 and R 8 , which are identical or different each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, —OH, —N(R′)(R″), —N(R′)COR″, —CN, —CONR′R″, —SO 2 NR′R″, —SO 2 R′, or nitro and trifluoromethyl, wherein R′ and R″ are identical or different each other, and are represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R 5 is hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, —OH, —N(R′)(R″), —N(R′)COR″, or nitro and trifluoromethyl, or R 5 together with one of R 6 and R 7 forms a ring having 5 or 6 carbon atoms, wherein R′ and R″ are identical or different each other, and are represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms, and

R 6 and R 7 , which are identical or different each other, are hydrogen, or an alkyl group having from 1 to 5 carbon atoms, or R 6 and R 7 together form a group C═O, or one of R 6 and R 7 , together with R 5 , forms a ring having 5 or 6 carbon atoms,

wherein when Y is —OH, A is different from an alkyl group having 1 carbon atom, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms, or alternatively at least one of R 1 to R 8 is different from hydrogen.